Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Alendronate (compound)


PubChem
Name: Alendronate
PubChem Compound ID: 10131134
Description: A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Molecular formula: C4H12NO7P2-
Molecular weight: 248.088 g/mol
DrugBank
Identification
Name: Alendronate
Name (isomeric): DB00630
Drug Type: small molecule
Description: A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Synonyms:
Alendronic acid; Acidum Alendronicum [INN-Latin]; Acido Alendronico [INN-Spanish]; Alendronate Sodium; Acide Alendronique [INN-French]
Brand: Onclast, Arendal, Fosamax Plus D, Alendros, Adronat, Fosamax
Brand name mixture: Fosavance(alendronate sodium + cholecalciferol)
Category: Antihypocalcemic Agents, Bisphosphonates, Bone Density Conservation Agents, Antiresorptives
CAS number: 66376-36-1
Pharmacology
Indication: For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
Pharmacology: Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women.
Mechanism of Action:
The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isopr...
show more »
Absorption: Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast.
Protein binding: 78%
Biotransformation: There is no evidence that alendronate is metabolized in humans or animals.
Route of elimination: Following a single IV dose of [14C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces.
Half Life: >10 years
Clearance: <200 mL/min [A single 10 mg IV dose]
Toxicity: Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis."
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Take 30-60 minutes before breakfast.
Take with a full glass of water.
Drug interaction:
KetorolacIncreased risk of gasrtic toxicity
PiroxicamIncreased risk of gastric toxicity
Mefenamic acidIncreased risk of gastric toxicity
DiflunisalIncreased risk of gastric toxicity
NabumetoneIncreased risk of gastric toxicity
show more »

Targets